Nuvation Bio Inc. (NUVB)
NUVB trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1811063/000119312526085584/0001193125-26-085584-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NUVB on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001811063 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $62.9M |
| Net income | -$204.6M |
| Operating income | -$213.1M |
| Net margin | -325.3% |
| Operating margin | -338.7% |
| Revenue growth | +699.0% |
| Cash | $164.1M |
| Total assets | $594.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 21.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $153.8M cash; operating cash flow -$26.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 353,017,638 (2026-10-30); 342,833,433 a year earlier; 218,944,053 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-02-10 |
| Auditor | KPMG LLP, New York, New York, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $118K, sold $9.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $45.0M | -$41.9M | -$38.6M | $153.8M | $285.4M | $201.7M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $31.7M | -$62.8M | -$43.0M | $258.6M | $248.5M | $169.9M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $83.2M | $5.4M | $5.1M | $125.4M | $53.1M | $143.0M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $41.9M | -$36.6M | -$29.7M | $164.1M | $52.9M | $62.9M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $13.1M | -$55.8M | -$52.9M | $98.9M | $52.7M | $26.7M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $4.8M | -$59.0M | -$48.2M | $248.0M | $52.6M | $14.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $3.1M | -$53.2M | -$42.6M | $48.0M | $5.7M | $11.0M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $5.7M | -$49.4M | -$46.3M | $35.7M | $6.3M | $7.9M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-29 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 400 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.1% |
| 1 month | -15.5% |
| 3 months | -34.6% |
| Year to date | -55.5% |
| 1 year | -14.9% |
| From 52-week high | -58.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier